Paladin Labs and Endo Ventures, subsidiaries of Endo International (NASDAQ:ENDP) have announced that Health Canada’s approval of Envarsus PA is marketed in Canada by Paladin Labs. As quoted in the press release: “We are pleased to announce Health Canada’s approval of Envarsus PA™ in Canada,” said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. …

Paladin Labs and Endo Ventures, subsidiaries of Endo International (NASDAQ:ENDP) have announced that Health Canada’s approval of Envarsus PA is marketed in Canada by Paladin Labs.

As quoted in the press release:

“We are pleased to announce Health Canada’s approval of Envarsus PA^™ in Canada,” said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. “We believe the launch of Envarsus PA^™ will provide kidney or liver transplant patients with an important alternative in immunosuppression, enhancing therapeutic options for those patients and for healthcare providers. We are committed to supporting continued innovation in transplantation to help Canadian patients with unmet needs.”
About Transplantation
The kidney and liver are the two most transplanted organs in Canada, representing over 76% of all organ transplants performed each year¹. In patients with end-stage organ failure, organ transplantation is the only curative option and has been established as a life-saving intervention that can have a profound effect on patient outcomes, including health-related quality of life (HRQoL) and survival.^2-4 The most serious complication of transplantation is organ rejection and controlling the anti-transplant immune response is essential for a successful outcome.
About ENVARSUS PA^™
ENVARSUS PA^™ (tacrolimus prolonged-release tablets) is indicated for the prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients in combination with other immunosuppressants. Envarsus is currently marketed in Europe and in the US.